1-3 of 3
Ariela Noy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Free
Jacob D. Soumerai, Andrew D. Zelenetz, Craig H. Moskowitz, M. Lia Palomba, Paul A. Hamlin, Jr, Ariela Noy, David J. Straus, Alison J. Moskowitz, Anas Younes, Matthew J. Matasar, Steven M. Horwitz, Carol S. Portlock, Jason A. Konner, Mrinal M. Gounder, David M. Hyman, Martin H. Voss, Matthew G. Fury, Devika Gajria, Richard D. Carvajal, Alan L. Ho, Jan H. Beumer, Brian Kiesel, Zhigang Zhang, Alice Chen, Richard F. Little, Christine Jarjies, Thu O. Dang, Fallon France, Nishant Mishra, John F. Gerecitano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4119–4126.
https://doi.org/10.1158/1078-0432.CCR-16-3068
Published: 01 August 2017
View article titled, The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Open the PDF for The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma

Free
John Gerecitano, Carol Portlock, Paul Hamlin, Craig H. Moskowitz, Ariela Noy, David Straus, Philip Schulman, Otilia Dumitrescu, Debra Sarasohn, Jennifer Pappanicholaou, Alexia Iasonos, Zhigang Zhang, Qianxing Mo, Endri Horanlli, Celeste N. Rojas, Andrew D. Zelenetz, Owen A. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2493–2501.
https://doi.org/10.1158/1078-0432.CCR-10-1498
Published: 14 April 2011
View article titled, Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma
Open the PDF for Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma in another window
Journal Articles

Telomeres: The Long and Short of Developing Non-Hodgkin Lymphoma

Free
Ariela Noy
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7114–7115.
https://doi.org/10.1158/1078-0432.CCR-09-2233
Published: 30 November 2009
View article titled, Telomeres: The Long and Short of Developing Non-Hodgkin Lymphoma
Open the PDF for Telomeres: The Long and Short of Developing Non-Hodgkin Lymphoma in another window
Includes: Supplementary data